Web30. mar 2024. · Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a … Web09. mar 2024. · The phase 3 A.R.R.O.W. study demonstrated that treatment with once-weekly carfilzomib (70 mg/m2) and dexamethasone (once-weekly Kd70 mg/m2) …

PRIME PubMed Once weekly versus twice weekly carfilzomib …

WebOnce-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma (ARROW) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. WebThe purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib … goodwill battlefield blvd chesapeake va

Once weekly versus twice weekly carfilzomib dosing in patients with ...

Web01. jun 2024. · Once weekly carfilzomib at 70 mg/m2 significantly prolonged progression-free survival versus the twice weekly schedule. Overall safety was comparable … WebThe MTD of once-weekly carfilzomib proved to be 70 mg/m2over a 30-min infusion period, displaying good effi-cacy and tolerability. Based on these results, a phase III study … WebTwice a week carfilzomib at 27 mg/m2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring once-weekly … goodwill battle creek michigan